{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04954534",
      "OrgStudyIdInfo": {
        "OrgStudyId": "SARC-CR-01"
      },
      "Organization": {
        "OrgFullName": "Samsung Medical Center",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Exploratory Efficacy Study of NEUROSTEM® in Subjects Who Control Group of NEUROSTEM®",
      "OfficialTitle": "Exploratory Efficacy Study of NEUROSTEM® in Subjects Who Control Group of NEUROSTEM® Phase-I/IIa Clinical Trial"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2021",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 12, 2021",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 31, 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 30, 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "June 1, 2021",
      "StudyFirstSubmitQCDate": "July 7, 2021",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 8, 2021",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "July 8, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 14, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Duk Lyul Na",
        "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "Samsung Medical Center"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Samsung Medical Center",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Medipost Co Ltd.",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This study is to evaluate of Exploratory Efficacy of NEUROSTEM® in Subjects who control group of NEUROSTEM® Phase-I/IIa Clinical Trial"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Alzheimer's Disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Not Applicable"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "9",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "NEUROSTEM (hUCB-MSCs) - high dose",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "human umbilical cord blood-derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: human umbilical cord blood derived mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "human umbilical cord blood derived mesenchymal stem cells",
            "InterventionDescription": "High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "NEUROSTEM (hUCB-MSCs) - high dose"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "NEUROSTEM"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change from the baseline in ADAS-Cog",
            "PrimaryOutcomeDescription": "The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis using an 11-point AD Assessment Scale. It has a minimum score of 0 and a maximum severity score of 70, and a higher score indicates more impairment.",
            "PrimaryOutcomeTimeFrame": "4weeks,8weeks,12weeks,24 weeks after the first dose"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Change in CDR-SOB",
            "SecondaryOutcomeDescription": "The CDR-SOB(Clinical Dementia Rating, Sum of Boxes) is a global rating of dementia severity based on the clinician's interpretation of the history and examination. The range of this instrument is 0 to 18 with higher numbers indicating greater impairment.",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change from the baseline in K-MMSE(korean version)",
            "SecondaryOutcomeDescription": "The MMSE(Mini-Mental State Examination) is a brief, practical test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language) and results in a total possible score from 0 to 30, with higher scores indicating better function",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change from the baseline in CGA-NPI",
            "SecondaryOutcomeDescription": "Caregiver-administered Neuropsychiatric Inventory, Measure abnormal behavior. The score range is 0-144. A higher score means severe abnormal behavior.",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change from the baseline in SIB",
            "SecondaryOutcomeDescription": "The Severe Impairment Battery (SIB) is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best)",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "ADAS-Cog Response Rate",
            "SecondaryOutcomeDescription": "Alzheimer's Disease assessment Scale-Cognitive Subscale",
            "SecondaryOutcomeTimeFrame": "The ADAS-cog response is defined as no worsening (no change or improvement on ADAS-cog score) of the ADAS-cog score at 24 weeks after the first administration compared to the baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Change in CIBIC-plus",
            "SecondaryOutcomeDescription": "The Clinician's Interview-Based Impression of Change-plus(CIBIC-plus) is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening).",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          },
          {
            "SecondaryOutcomeMeasure": "Change from the baseline in CSF biomarkers",
            "SecondaryOutcomeDescription": "biomakrers analysis (Amyloid beta 42, Phosphorylated tau, Total tau, RBC, WBC, Protein, Glucose)",
            "SecondaryOutcomeTimeFrame": "24 weeks after the first dose"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nSubjects who have been treated with placebo in phase 1/2a clinical trial of NEUROSTEM®\nSubjects who voluntarily decided to participate and signed the consent form after receiving explanations on the clinical trial (in case it is difficult for the participant to sign, the consent of the legal representative)\n\nExclusion Criteria:\n\nHistory of stroke within 3 months prior to study enrollment\nSevere liver disorder (equivalent to double the normal values of ALT and AST) at Visit 1\nSevere kidney disorder (serum creatinine ≥1.5mg/dL) at Visit 1\n\nAbnormal Laboratory findings at Visit 1\n\nHemoglobin < 9.5 g/dL for male and <9.0 g/dL for female\nTotal WBC Count < 3000/mm3\nTotal Bilirubin >= 3 mg/dL\nSuspected active lung disease based on chest X-ray at Visit 1\nBleeding disorder (abnormal blood coagulation test result (i.e. platelet count of < 137,000/mm3, PT ≥ 1.5 INR, or aPTT ≥ 1.5 x control anti-coagulant or anti-platelet, without anticoagulant or anti-platelet therapy)\nDiagnosis of cancer (of any body system, including brain tumor)\nContraindicated for any of the tests performed during the clinical trial period (for example, MRI, CT, PET)\nWhom the principal investigator considers inappropriate for participation in the study due to any reasons other than those listed above",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "50 Years",
      "MaximumAge": "85 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Heejin kim, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+82-2-3410-1947",
            "CentralContactEMail": "evekhj@gmail.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Duk L. Na, MD, PhD",
            "OverallOfficialAffiliation": "Samsung Medical Center",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Samsung Medical Center",
            "LocationCity": "Seoul",
            "LocationZip": "135-710",
            "LocationCountry": "Korea, Republic of"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000000544",
            "ConditionMeshTerm": "Alzheimer Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000003704",
            "ConditionAncestorTerm": "Dementia"
          },
          {
            "ConditionAncestorId": "D000001927",
            "ConditionAncestorTerm": "Brain Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000024801",
            "ConditionAncestorTerm": "Tauopathies"
          },
          {
            "ConditionAncestorId": "D000019636",
            "ConditionAncestorTerm": "Neurodegenerative Diseases"
          },
          {
            "ConditionAncestorId": "D000019965",
            "ConditionAncestorTerm": "Neurocognitive Disorders"
          },
          {
            "ConditionAncestorId": "D000001523",
            "ConditionAncestorTerm": "Mental Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3037",
            "ConditionBrowseLeafName": "Alzheimer Disease",
            "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6056",
            "ConditionBrowseLeafName": "Dementia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4356",
            "ConditionBrowseLeafName": "Brain Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22155",
            "ConditionBrowseLeafName": "Tauopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20711",
            "ConditionBrowseLeafName": "Neurodegenerative Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20989",
            "ConditionBrowseLeafName": "Neurocognitive Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3967",
            "ConditionBrowseLeafName": "Mental Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13625",
            "ConditionBrowseLeafName": "Psychotic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2192",
            "ConditionBrowseLeafName": "Familial Alzheimer Disease",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXM",
            "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}